Summary. Erythrocytes from diabetic patients before and after treatment with the aldose reductase inhibitor, sorbinil, were analyzed by a capillary gas chromatographic method for sorbitol and myo-inositol. The mean erythrocyte sorbitol level in the diabetic patients was significantly higher than in the control subjects (13.1+0.9 and 5.2 _+ 0.3 nmol/ml erythrocytes, respectively, mean_ SEM, p< 0.001). The mean erythrocyte myo-inositol level in diabetic patients was not different from that in control subjects (43.2 + 2.9 and 40.5 + 1.9 nmol/ ml erythrocytes, respectively). Sorbinil treatment reduced the elevated sorbitol levels in the diabetic patients to normal or slightly below normal, but did not affect the erythrocyte myoinositol concentration. It is concluded that the erythrocyte is not a suitable model to monitor a possible effect of sorbinil on myo-inositol concentration in less accessible tissues.
The induction of experimental diabetes leads to a decrease in nerve conduction velocity, which is associated with increased levels of glucose, sorbitol and fructose, and decreased levels of myo-inositol in the nerve tissue [1] [2] [3] . Insulin treatment can correct these metabolic abnormalities and will attenuate nerve conduction velocity defects. A restoration of nerve conduction velocity can also be achieved either by reducing nerve sorbitol concentrations to normal by treatment with aldose reductase inhibitors, or by restoring to normal the nerve myo-inositol concentration by an increased dietary intake of myo-inositol [3] [4] [5] .
Recently a relationship between increased sorbitol concentration and decreased myo-inositol concentration in peripheral nerves of diabetic rats has been demonstrated [6, 7] . Treatment of streptozotocin-diabetic rats with aldose reductase inhibitors, which restore nerve sorbitol concentrations to normal, also corrected the reduced myo-inositol concentration in nerve.
In diabetic patients evidence of metabolic abnormalities in the nerve tissue has been obtained from measurement of polyols in cerebrospinal fluid [8, 9] and sciatic nerves obtained post-mortem [10] . To study the sorbitol pathway activity in vivo, erythrocytes can be used as a model for less accessible tissues, and the effects of aldose reductase inhibitors have been monitored by measuring erythrocyte sorbitol concentrations [11, 12] .
The aim of the present study was to investigate the effect of the aldose reductase inhibitor, sorbinil, on sorbitol and myo-Inositol concentrations in erythrocytes, myo-Inositol and sorbitol concentrations were measured in erythrocytes from Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetic patients before and after sorbinil treatment, using a specific mass-spectrometric controlled capillary gas chromatographic assay.
Subjects and methods

Subjects
Twenty-eight Type 1 and Type 2 diabetic patients participated, after giving informed consent, in a double-blind parallel-group placebocontrolled study. Approval was given by the Ethical Committee of the Free University Hospital, Amsterdam. Clinical details of the patients at the start of the study are given in Table t . A 4-week placebo period was followed by a 12-week sorbinil or placebo period and subsequently by a 4-week placebo period. The sorbinil dose was 200 mg daily. After 4, 8, 12, 16 and 20 weeks (periods I, 2, 3, 4 and 5, respectively) blood was sampled between 13.00 and 16.00 h for the determination of erythrocyte myo-inositol (24patients), erythrocyte sorbitol (28 patients), glycosylated haemoglobin (HbA0 and plasma sorbinil. Reference values were obtained from heparinized blood samples of 30 non-diabetic healthy volunteers after an overnight fast. This control group consisted of 12 female and 18 male subjects, the mean ___ SD age was 35.2 + 9.5 years (range 20-62 years).
Methods
Erythrocyte myo-inositol and sorbitol were determined by a capillary gas chromatographic method as described previously [13] . The identities of myo-inositol and sorbitol and their single elution from the capillary column were confirmed by mass-spectrometry. Sorbitol and myo-inositol values are expressed as nmol/ml packed erythrocytes; 
Results
Sorbitol and myo-inositol levels in erythrocytes from diabetic patients during placebo or sorbinil treatment are shown in Figure 1 . The mean HbA1 in the sorbinil group during placebo was 10.3 + 0.4% and during sorbinil 10.2 +_ 0.4%. In the placebo group, HbAt was 10.6 +_ 0.2%. The mean plasma sorbinil level during treatment with 200 mg sorbinil daily was 6,4 + 0.6 ~g/ml. The mean erythrocyte sorbitol level in diabetic patients was significantly higher than in control subjects (13.1+0.9 and 5.2+0.3 nmol/ml erythrocytes, respectively, p<0.001). Treatment with 200mg sorbinil daily reduced the erythrocyte sorbitol values to normal (period 4) or slightly below normal (period 2: p < 0.001 ; period 3:p< 0.01). The mean erythrocyte myo-inositol concentration in diabetic patients was similar to that in control subjects (43.2 + 2.9 and 40,5 + 1.9 nmol/ml erythrocytes, respectively). The range in erythrocyte myo-inositol concentrations in diabetic patients was larger than in control subjects (19-131 and 29-58 nmol/ ml erythrocytes, respectively) due to high values in erythrocytes from two patients (95 and 131 nmol/ml erythrocytes). These patients showed marked proteinuria and elevated plasma creatinine levels (> 150 p~mol/1). Sorbinil treatment of diabetic patients did not change erythrocyte myo-inositol levels. 
Discussion
The treatment of diabetic patients with 200 mg sorbinil daily for 4 weeks reduced erythrocyte sorbitol concentrations by 75%, resulting in values slightly below normal. This reduction is greater than that found by Malone et al. [12] after treatment of Type I diabetic patients with a daily dose of 250 mg sorbinil (52%). This difference can probably be explained by the methods used to determine erythrocyte sorbitol. The specificity of the sorbitol dehydrogenase method, as used by Malone et al, depends on the specificity of the commercially available enzyme preparation [13, 16] . Especially when erythrocyte sorbitol levels are low, as can be expected after sorbinil treatment, the contribution of non-specific components can be relatively high. Measurement of both sorbitol and myo-inositol in nerve tissue after induction of experimental diabetes and during treatment has given information about the metabolic abnormalities associated with reduced nerve conduction velocity [6, 7] . In clinical studies more accessible tissues have to be chosen to monitor the possible biochemical effects of dietary myo-inositol or sorbinil treatment. Recently Gregersen et al. [17] investigated the effect of oral supplementation of myo-inositol on its concentration in human plasma, erythrocytes, urine and muscle tissue in four diabetic and four control subjects. They found no indication of a lack of myo-inositol in blood or tissue from diabetic patients. The dietary myoinositol supplement did increase plasma and erythrocyte myo-inositol, in the diabetic patients even more than in control subjects, but did not affect impaired nerve conduction velocity.
In the present study, no difference was found between the mean myo-inositol content of erythrocytes from diabetic and control subjects. The range of erythrocyte myo-inositol in the diabetic patients, however, was larger than in control subjects, due to high values in erythrocytes from two insulin-dependent patients, who showed marked proteinuria and elevated plasma creatinine values. The erythrocyte myo-inositol levels probably reflect plasma myo-inositol concentrations, as was shown by Gregersen et al. [17] and by Dawson and Freinkel [18] . A supranormal rise in plasma myo-inositol concentration after a meal or an oral myo-inositol load have been demonstrated by Clements and Reynertson [19] in newly-diagnosed untreated diabetic patients. This myo-inositol intolerance was, however, restored to normal by insulin therapy. In insulin-treated diabetic patients, increased fasting plasma myo-inositol concentrations have been found only in those patients who had impaired renal function [19, 20] . The high myoinositol levels which we found in erythrocytes from some diabetic patients might therefore be explained by their impaired renal function.
Sorbinil treatment did not affect erythrocyte myoinositol content, despite restoration of intracellular sorbitol levels to normal. The effect of sorbinil treatment on myo-inositol concentrations in nerve tissue from diabetic patients is still unknown. From our data we conclude that a possible effect of sorbinil on nerve myo-inositol levels will not be reflected in erythrocyte myo-inositol concentrations. The effect of sorbinil on intracellular sorbitol concentrations can, however, be monitored by measuring erythrocyte sorbitol concentrations.
